ezetimibeatorvastatin trade names liptruzet atozet cholesterol lowering combination drug united states approved may food drug administration treatment elevated lowdensity lipoprotein ldl patients primary mixed hyperlipidemia adjunctive therapy also approved reduce elevated total cholesterol elevated ldl patients diagnosed homozygous familial hypercholesterolemia adjunctive treatment hyperlipidemia cardiologists opposed approval combination reduced ldl cholesterol clinical trial reduce heart disease clinical trial studying endpoints heart attacks strokes heartrelated deaths scheduled conclude liptruzet withdrawn sale manufacturer june reasons safety combination drug works reduce cholesterol levels two different pathways ezetimibe component medication works inhibiting cholesterol absorption food atorvastatin component inhibits intrinsic cholesterol production commonly reported adverse effects httpsenwikipediaorgwikiezetimibeatorvastatin